{
    "nct_id": "NCT03498378",
    "official_title": "A Phase I Study of Avelumab, Palbociclib, and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
    "inclusion_criteria": "* Histologically or cytologically proven squamous cell carcinoma of the head and neck not amenable to curative intent therapy.\n* Presence of measurable tumor lesions per RECIST criteria v1.1\n* Life expectancy greater than 12 weeks.\n* Adequate hematologic, hepatic, and renal function\n* Negative serum or urine pregnancy test for women of child bearing potential\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior therapy with an EGFR inhibitor or PD-1 or PD-L1 inhibitor in the recurrent or metastatic setting\n* Uncontrolled central nervous system metastases (stable metastases permitted)\n* Chemotherapy 28 days prior to first administration of study treatment and/or monoclonal antibody â‰¤8 weeks prior to first administration of study treatment.\n* History of other malignancies,\n* Concurrent systemic immunosuppressant therapy (eg, cyclosporine A, tacrolimus, etc., or chronic administration of >10 mg/day of prednisone or equivalent)\n* Prior organ transplantation\n* Known history of human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV).",
    "miscellaneous_criteria": ""
}